Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Double-blind Extension Study of Ritlecitinib in Severe Alopecia Areata (B7981028)
jRCT2041250189Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of ritlecitinib tosilate in alopecia areata, alopecia areata totalis (AT) and alopecia universalis (AU) (2 arms), sponsored by Pfizer. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of serious adverse events and AEs leading to discontinuation. Started Apr 2026; status: recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areataalopecia areata totalis (AT)alopecia universalis (AU)
Beyond the preview
Go deeper on jRCT2041250189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250189.